Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

SARS-CoV-2 Vaccine Technologies and Pivotal Trials Data: General Population and Special Groups

Sars-Cov-2-Vaccine-Technologies-and-Pivotal-Trials-Data-General-Population-and-Special-Groups-1000x250px

SARS-CoV-2 Vaccine Technologies and Pivotal Trials Data: General Population and Special Groups

The programme is designed to offer expert opinion exchange and provide some considerations on which vaccine technology may better serve patients with co-morbidity and immune dysfunction with an emphasis on cancer, and to discuss available clinical trial data.

SARS-CoV-2 Vaccine Technologies and Pivotal Trials Data:
General Population and Special Groups

Chair: Anne-Marie Dingemans
Speakers: Nicola Giesen, Marco Cavaleri, Paul Heath

Watch now*

Watch now on demand ​(Aired live on 2 February 2021 at 17.30 CET)

*The ESMO Webinar Series is freely available to all healthcare professionals working in Oncology. 

If you are an ESMO Member or already have a free ESMO Account, you can log in and watch the ESMO Webinar Series using your existing ESMO Account.

Don’t have an ESMO Account?

Please set up a free ESMO Account now to access the ESMO Webinars Series.

Programme

  • Welcome and Introduction, Prof. Anne-Marie Dingemans, Erasmus MC Cancer Institute, University Medical Center Rotterdam, dept. of Respiratory Medicine, Rotterdam, Netherlands
  • General Vaccine Policies (non-COVID-19) in Patients with Cancer: Indication, Safety, Efficacy, Dr. Nicola Giesen, Dept. of Haematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
  • What an Oncologist Should Know About SARS-CoV-2 Vaccine Technologies: mRNA, viral vector and peptide-based?, Dr. Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, European Medicines Agency, Amsterdam, Netherlands
  • SARS-CoV-2 Vaccine Trials Data: Evidence for Efficacy and Safety in the General Population and in Special Patient Groups (Co-morbidity, Immune Dysfunction, Cancer), Prof. Paul Heath, St George’s University Hospital NHS Foundation Trust, University of London, London, UK
  • Q&A
  • Closing Remarks, Prof. Anne-Marie Dingemans, Erasmus MC Cancer Institute, University Medical Center Rotterdam, dept. of Respiratory Medicine, Rotterdam, Netherlands

Learning objectives: 

  • To provide essential principles on vaccinations in patients with cancer
  • To understand the basics in different technologies used for development of SARS-CoV-2 vaccines
  • To understand which SARS-CoV-2 vaccine technology may serve better different population groups
  • To understand potential differences in terms of SARS-CoV-2 vaccine technologies that might be important in terms of immune response and safety in patients with co-morbidity and immune dysfunction, by giving a special emphasis on cancer
  • To evaluate SARS-CoV-2 vaccine trials data in terms of efficacy in the general population and in the patient groups with co-morbidity, immune dysfunction and cancer
  • To evaluate SARS-CoV-2 vaccine trials data in terms of safety in the general population and in the patient groups with co-morbidity, immune dysfunction and cancer

Watch now*

Watch now on demand ​(Aired live on 2 February 2021 at 17.30 CET)

*The ESMO Webinar Series is freely available to all healthcare professionals working in Oncology. 

If you are an ESMO Member or already have a free ESMO Account, you can log in and watch the ESMO Webinar Series using your existing ESMO Account.

Don’t have an ESMO Account?

Please set up a free ESMO Account now to access the ESMO Webinars Series.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings